Axio has partnered with over 6,000+ brick-and-mortar stores as well as popular e-commerce platforms
Axio Biosolutions has announced its strategic decision to enter the retail space in India. Axio is set to make its best-in-class wound care and COVID essential products available for Indian homes across 50 cities in the next one year.
The B2C / D2C move is aimed at consolidating the company’s leadership position in the global advanced wound care space. Funded by Ratan Tata, Omidyar Network, Accel and Chiratae Ventures, Axio has seen exponential growth in the international markets in the last few years. With Axio’s entry into retail, consumers will now have access to products such as: ASK+ Kits, MaxioCel and RESIST+.
Commenting on the company’s latest development, Leo Mavely, CEO and Founder, Axio Biosolutions, said, “At Axio Biosolutions, we have always been driven by the vision to make best-in-class wound care accessible to all. Over the next two months, we will be working towards ensuring that all Indian households will have access to our entire range of wound care products along with Covid essential supplies. Timely home care can make all the difference in critical situations, particularly at a time when our medical system is overburdened.”
In addition to the products being available on the company’s online store, Axio has partnered with over 6,000+ brick-and-mortar stores as well as popular e-commerce platforms, to deliver its products directly to the end consumer.
